MC5-A Scrambler Therapy in Reducing Peripheral Neuropathy Caused by Chemotherapy

Inclusion Criteria: * Received neurotoxic chemotherapy (including taxanes-such as paclitaxel or docetaxel, or platinum-based compounds such as carboplatin or cis-platinum or oxaliplatin, or vinca alkaloids such as vincristine, vinblastine, or vinorelbine, or proteosome inhibitors such as bortezomib); Note: this neurotoxic chemotherapy must have been completed more than 3 months prior to when they enter this trial * Pain or symptoms of peripheral neuropathy in the feet of \>= 1 month (30 days) duration attributed to chemotherapy-induced peripheral neuropathy, for which the patient wants intervention * Participants have to relate that numbness, tingling or pain in their toes/feet was at least a four out of ten problem during the prior week, on a 0-10 scale where zero was no problem and ten was the worst possible problem * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 0, 1, or 2 * Life expectancy \>= 3 months (90 days) * Ability to complete questionnaire(s) by themselves or with assistance * Provide informed written consent * No change in scheduled analgesic agents for at least one week Exclusion Criteria: * Pregnant women * CIPN troubles in the lower extremities more proximal to the mid calf * Patients with implantable drug delivery systems, e.g. Medtronic Synchromed * Patients with heart stents or metal implants such as pacemakers, automatic defibrillators, aneurysm clips, vena cava clips and skull plates; (metal implants for orthopedic repair, e.g. pins, clips, plates, cages, joint replacements are allowed as are central venous access devices) * Patients with a history of myocardial infarction or ischemic heart disease within the past six months * Patients with history of epilepsy, brain damage, use of anti-convulsants, symptomatic brain metastases * Other identified causes of painful lower extremity paresthesias existing prior to chemotherapy (e.g., radiation or malignant plexopathy, lumbar or cervical radiculopathy, pre-existing peripheral neuropathy of another etiology: B12 deficiency, Acquired Immunodeficiency Syndrome \[AIDS\], monoclonal gammopathy, diabetes, heavy metal poisoning amyloidosis, syphilis, hyperthyroidism or hypothyroidism, inherited neuropathy, etc.) * Skin conditions such as open sores that would prevent proper application of the electrodes * Other medical or other condition(s) that in the opinion of the investigators might compromise the objectives of the study * Prior treatment with Calmare MC-5A therapy for any reason or knowledge of application procedure